By following tumor growth, we found that tumors in NS and T cells groups grew promptly, while 100 μg HLA-A2/KRAS G12V-CD3 BiTE modified activated T cells caused significantly tumor regression (Figures 6B, E). The gene discussed is KRAS; the disease is neoplasm.